News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cenix BioScience GmbH and CellCentric Ltd. Sign Framework Research Agreement for RNAi-Based Target Validation



3/20/2008 8:44:55 AM

DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has signed a framework research agreement to support CellCentric Ltd, a biotechnology company unlocking epigenetic control mechanisms, through cell-based validation of novel therapeutic drug targets for oncology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES